Dayvigo Shortage: What Providers and Prescribers Need to Know in 2026

Dayvigo Availability in 2026: A Provider Briefing

If your patients have been reporting difficulty filling Dayvigo (Lemborexant) prescriptions, you're hearing a real and growing concern. While Dayvigo is not on the FDA's official drug shortage list, the practical reality for many patients is that their local pharmacy doesn't carry it — and the barriers to access go beyond simple supply and demand.

This briefing covers the current availability picture, prescribing implications, cost and access challenges, clinical considerations, and tools you can use to help your patients get their medication filled promptly.

Timeline: How We Got Here

Understanding Dayvigo's current market position helps contextualize the access issues your patients face:

• December 2019: FDA approves Lemborexant (Dayvigo) for the treatment of insomnia in adults
• April 2020: DEA places Lemborexant in Schedule IV; Eisai launches Dayvigo commercially in the U.S.
• 2020–2024: DORA class gains clinical traction but remains behind benzodiazepine receptor agonists (Z-drugs) and sedating antidepressants in prescription volume
• 2022: Quviviq (Daridorexant) enters the market as the third DORA, expanding the class but fragmenting market share
• 2026: Dayvigo remains brand-only. Some market exclusivity periods expire, but core patents extend to at least 2035. No generic entry expected in the near term.

Current Supply Status

Dayvigo is not in shortage. Eisai continues to manufacture and distribute both the 5 mg and 10 mg tablets through standard pharmaceutical wholesalers. The supply chain from manufacturer to distributor remains intact.

The access challenge occurs at the pharmacy level. Multiple factors converge to limit local availability:

• Low prescription volume: Chain pharmacies stock based on fill frequency. Many locations fill fewer than 5 Dayvigo prescriptions per month, making it an uneconomical inventory item.
• High acquisition cost: At $400–$500 per month retail, Dayvigo ties up significant inventory capital relative to the number of prescriptions filled.
• Insurance friction: Frequent PA denials reduce successful fills, further decreasing perceived demand at the pharmacy level.
• Brand-only status: No generic alternatives exist for Lemborexant specifically, limiting supply chain redundancy that typically improves availability.
• DORA class fragmentation: With three DORAs now on the market (Dayvigo, Belsomra, Quviviq), individual product demand is split, reducing the likelihood any single DORA is routinely stocked.

Prescribing Implications

Several factors directly affect your prescribing workflow when choosing Dayvigo:

Prior Authorization Is Common

The majority of commercial and Medicare Part D plans require prior authorization for Dayvigo. Many also mandate step therapy — typically requiring a trial and failure of generic Zolpidem or another first-line agent before authorizing a DORA. Plan ahead by initiating the PA process at the time of prescribing rather than after the patient arrives at the pharmacy.

Key documentation to include in PA submissions:

• Insomnia diagnosis with appropriate ICD-10 codes (G47.00, G47.01, G47.09)
• Prior medication trials and documented inadequate response or adverse effects
• Clinical rationale for DORA therapy over first-line agents
• Relevant sleep study results, if available
• Comorbidities that favor DORA use (e.g., substance use history, fall risk in elderly patients)

Schedule IV Status

As a Schedule IV controlled substance, Dayvigo carries standard DEA prescribing requirements. E-prescribing of controlled substances (EPCS) is required in most states. Refill limits and monitoring apply per state regulations. Ensure your practice's EPCS system is properly configured for Dayvigo prescriptions.

Dosing Considerations

The recommended starting dose is 5 mg nightly, with the option to increase to 10 mg based on clinical response. Instruct patients to take Dayvigo immediately before bedtime with at least 7 hours remaining before the planned time of awakening. Key dose adjustments:

• Moderate hepatic impairment: Do not exceed 5 mg
• Severe hepatic impairment: Not recommended
• Concomitant strong CYP3A4 inhibitors (e.g., itraconazole, clarithromycin): Do not exceed 5 mg
• Concomitant strong/moderate CYP3A4 inducers (e.g., rifampin, carbamazepine, phenytoin): Avoid use — these agents significantly reduce Lemborexant plasma concentrations

Advise patients that taking Dayvigo with or shortly after a heavy meal may delay onset of action. Alcohol should be avoided. For a detailed drug interaction reference, see: Dayvigo Drug Interactions: What to Avoid.

Contraindications and Cautions

Dayvigo is contraindicated in patients with narcolepsy. Exercise clinical caution in patients with:

• History of depression or suicidal ideation — monitor for worsening mood
• Substance use disorders — although abuse potential is lower than Z-drugs, Dayvigo is still a controlled substance
• Obstructive sleep apnea or COPD — limited data in patients with moderate-to-severe respiratory impairment
• History of complex sleep behaviors — discontinue immediately if reported
• Elderly patients — while Dayvigo has been studied in older adults and may be preferred over Z-drugs due to lower fall risk, start at 5 mg and monitor

Safety Monitoring

Although Dayvigo does not carry a boxed warning, prominent label warnings address:

• Complex sleep behaviors: Sleepwalking, sleep-driving, and other activities performed while not fully awake. Discontinue if reported.
• Next-day impairment: Counsel patients about potential decreased alertness, especially when initiating therapy or increasing dose.
• Sleep paralysis and hypnagogic/hypnopompic hallucinations: Occur infrequently but can be distressing.
• Cataplexy-like symptoms: Transient leg weakness has been reported, consistent with the mechanism of orexin receptor antagonism.

Cost and Access in 2026

Cost remains one of the primary barriers for patients:

• Average retail price: $400–$500/month (30 tablets)
• GoodRx coupon price: Starting around $135/month
• Eisai Instant Savings Card: As low as $10 copay for commercially insured patients (not valid for Medicare, Medicaid, or Tricare)
• Eisai Patient Assistance Program: Free medication for qualifying patients based on financial need

When discussing cost with patients, consider directing them to: How to Save Money on Dayvigo in 2026.

For a provider-focused savings reference, see: How to Help Patients Save Money on Dayvigo: A Provider's Guide.

Clinical Evidence Update

Recent clinical data reinforces Dayvigo's position as a viable first-line DORA:

• SUNRISE 1 trial: Demonstrated significant improvement in sleep onset latency versus placebo in adults with insomnia
• SUNRISE 2 trial: Showed sustained efficacy over 12 months with improvements in both sleep onset and sleep maintenance, supporting long-term use
• Elderly populations: Subgroup analyses and dedicated studies in patients aged 65+ show favorable efficacy with a safety profile that may be preferable to Z-drugs, particularly regarding fall risk and cognitive effects
• Head-to-head data: SUNRISE 1 included a Zolpidem ER comparator arm, providing relative efficacy context

These data points can be valuable when completing prior authorization documentation and clinical rationale for DORA therapy selection.

Tools and Resources for Providers

Medfinder for Providers

Medfinder offers a provider-facing tool that allows you and your staff to check real-time pharmacy availability for Dayvigo in your patient's area. This can be incorporated into your prescribing workflow to help patients locate stock before they leave the office. Consider making this a standard step when prescribing any brand-name or specialty medication.

Eisai Patient Support

Eisai's reimbursement support line can assist with prior authorizations, appeals, and connecting patients with financial assistance programs. Contact: 1-800-657-7613 or visit eisaipatientsupport.com. Their team can also provide sample PA letters and clinical documentation templates.

Alternative DORA Options

If Dayvigo is inaccessible for a particular patient, consider these alternatives within the DORA class:

• Belsomra (Suvorexant): Available in 5, 10, 15, and 20 mg. Similar efficacy profile. May have different formulary placement on certain plans.
• Quviviq (Daridorexant): Available in 25 and 50 mg. Shorter half-life may reduce next-day somnolence. FDA-approved 2022.

Outside the DORA class, generic Zolpidem (IR and ER), Eszopiclone, and low-dose Doxepin (Silenor) remain widely available and may serve as interim alternatives while access issues are resolved.

Patient Communication Considerations

When prescribing Dayvigo, proactive patient counseling can prevent many of the access-related callbacks that consume clinical and administrative time:

• Set expectations on availability: Inform patients that Dayvigo may not be immediately available at all pharmacies and that special-ordering is normal and typically takes 1–3 business days.
• Discuss cost upfront: Patients who are surprised by the price at the pharmacy counter are significantly more likely to abandon the prescription. Address cost proactively and provide savings resources.
• Explain the PA process: Let patients know that prior authorization may be required and that your office will handle the submission. Provide a realistic timeline (48–72 hours typical).
• Provide a backup plan: If access is delayed, patients should know they can call your office for a temporary alternative rather than going without sleep treatment.

Looking Ahead

Several trends may affect Dayvigo access and prescribing in the coming years:

• No near-term generic competition: Core patents extend to 2035, so pricing pressure from generics is unlikely soon. Providers should plan for continued brand-only availability.
• Expanding DORA evidence: Ongoing studies in elderly populations, comorbid insomnia, and long-term safety may strengthen the clinical case for DORAs over Z-drugs and influence formulary decisions.
• Formulary shifts: As more payers recognize DORA advantages (lower abuse potential, fewer complex sleep behaviors, favorable elderly safety profile), formulary access may improve.
• Telehealth prescribing: The growth of telehealth sleep medicine is increasing Dayvigo prescribing, which may drive better pharmacy stocking over time as demand grows.
• Guideline evolution: Updated insomnia treatment guidelines may increasingly position DORAs as first-line options, which could accelerate insurer coverage and reduce PA requirements.
• Real-world evidence: Post-marketing surveillance data and real-world effectiveness studies will continue to inform the risk-benefit assessment and may support broader use.

Final Thoughts

Dayvigo remains a clinically valuable option for insomnia — particularly for patients who haven't responded well to older agents, who are at risk for dependence, or who are in populations where Z-drugs carry elevated risk (elderly, substance use history). The access challenges are real but manageable with proactive prescribing, awareness of insurance requirements, and use of tools like Medfinder for Providers.

For a practical step-by-step guide on helping patients find Dayvigo, see: How to Help Your Patients Find Dayvigo in Stock: A Provider's Guide.